Agreed, assuming they can keep the same sales trajectory through the year without increasing costs, indeed their guidance is a slight decrease in costs. Lets assume they can get by with no R&D and lower costs, but yet increasing sales. You are still looking at a new capital raise in Q4 '19, which would obviously be dilutive to the current share price.
Agreed, assuming they can keep the same sales trajectory through...
-
- There are more pages in this discussion • 11 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
